Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Arcus Biosciences, Inc. (RCUS) Normalized Income after Taxes data is not available for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$160.00M |
|
-- |
|
-- |
|
$160.00M |
|
$168.00M |
|
$-8.00M |
|
$8.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Normalized Income after Taxes |
-- |
$-8.00M |
|
$-9.00M |
|
106.10M |
|
106.50M |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$946.00M |
|
$44.00M |
|
$129.00M |
|
$1.07B |
|
$210.00M |
|
$97.00M |
|
$316.00M |
|
$526.00M |
|
$549.00M |
|
$549.00M |
|
$549.00M |
|
106.40M |
|
| Cash Flow Statement Financials | |
$-265.00M |
|
$169.00M |
|
$194.00M |
|
$153.00M |
|
$251.00M |
|
$98.00M |
|
$31.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.50 |
|
-- |
|
-- |
|
0.15 |
|
0.18 |
|
100.00% |
|
-5.00% |
|
-5.00% |
|
-- |
|
-- |
|
-- |
|
$-266.00M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
-- |
|
10.67 |
|
8.44 |
|
-- |
|
-- |
|
-- |
|
-- |
|
$5.16 |
|
$-2.50 |
|
$-2.49 |
|